Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome
Clara Matute‐Blanch(Vall d'Hebron Institut de Recerca), Manuel Comabella(Universitat Autònoma de Barcelona), Sara Llufriú(Hospital Clínic de Barcelona), Luciana Midaglia(Universitat Autònoma de Barcelona), Harald Hegen(Innsbruck Medical University), Roberto Álvarez‐Lafuente(Hospital Clínico San Carlos), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Antonio Sánchez(Institut d'Estadística de Catalunya), Mar Tintoré(Vall d'Hebron Hospital Universitari), René Carlos Calderón Robles(Institut d'Investigació Biomèdica de Girona), Uwe K. Zettl(University of Rostock), Florian Deisenhammer(University of Vienna), Ángela Vidal‐Jordana(Universitat Autònoma de Barcelona), Ina Schroeder(University of Rostock), Konrad Rejdak(Medical University of Lublin), В. Д. Назаров(First Pavlov State Medical University of St. Petersburg), Ester Quintana(Institut d'Investigació Biomèdica de Girona), Álex Sánchez‐Pla(Universitat de Barcelona), Eva Havrdová(Charles University), Jordi Río(Universitat Autònoma de Barcelona), Daniela Galimberti(University of Milan), Lluís Ramió‐Torrentà, Luisa María Villar(Evidence (Italy)), Jelena Drulović(University of Belgrade), Albert Saiz(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Evgeniy Evdoshenko(First Pavlov State Medical University of St. Petersburg), José C. Álvarez‐Cermeño(Hospital Universitario Ramón y Cajal), С. В. Лапин(First Pavlov State Medical University of St. Petersburg), Antonio Garcı́a-Merino, Gleb Makshakov(First Pavlov State Medical University of St. Petersburg)
Cited by 161
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k